Question to the Department for Business and Trade:

To ask His Majesty's Government what mitigations they have secured under the United States' "Most Favoured Nation" drug pricing initiative as part of the UK–US Economic Prosperity Deal.

The US has committed to ensuring that access to medicines and launches of new innovative medicines in the UK are not inadvertently impacted by the US’s ‘Most Favoured Nation’ policy, thereby reducing the risk to the UK where the NHS has managed to secure lower prices for medicines.

Further work to finalise underpinning details is ongoing.